E Fund Management’s PMV Pharmaceuticals PMVP Stock Holding History

E Fund Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,884	Closed	-$121K	–	350
2022 Q4	$121K	Sell	13,884 -6,000	-30%	-$64K	0.01%	323
2022 Q3	$237K	Sell	19,884 -7,617	-28%	-$110K	0.02%	275
2022 Q2	$392K	Buy	+27,501	New	+$400K	0.04%	192

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

E Fund Management's PMVP Position: Q1 2023 in Review

E Fund Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2023, closing a stake of 13,884 shares — an estimated $121K sold.

E Fund Management first reported a position in PMVP in Q2 2022 and held it in 3 quarters. The position peaked at $392K in Q2 2022. 111 funds tracked by Wall St. Rank hold PMVP as of Q1 2023.

E Fund Management reported no remaining PMV Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
E Fund Management sold 13,884 PMV Pharmaceuticals shares in Q1 2023, an estimated $121K.
E Fund Management first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 3 quarters.
E Fund Management's PMV Pharmaceuticals position peaked at $392K in Q2 2022.
111 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2023.

Based on E Fund Management's 13F filing for Q1 2023, filed 11 May 2023.